Redenšek Trampuž, Sara
van Riet, Sander
Nordling, Åsa
Ingelman-Sundberg, Magnus
Funding for this research was provided by:
European Research Council (742020)
Karolinska Institute
Article History
Received: 29 August 2023
Accepted: 6 December 2023
First Online: 16 January 2024
Competing interests
: Magnus Ingelman-Sundberg is co-founder and co-owner of HepaPredict AB. The other authors declare no conflicts of interest. No author has a non-financial interest in the study.